| Mary Catherine Boyle, MD | |
|
1600 Pacific Ave, Natrona Heights, PA 15065-2138 | |
| (724) 224-3900 | |
| (724) 224-9010 |
| Full Name | Mary Catherine Boyle |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1600 Pacific Ave, Natrona Heights, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619970886 | NPI | - | NPPES |
| 000157245002 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD056860L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Catherine Boyle, MD 11279 Perry Hwy, Ste 450, Wexford, PA 15090-9303 Ph: (724) 933-1100 | Mary Catherine Boyle, MD 1600 Pacific Ave, Natrona Heights, PA 15065-2138 Ph: (724) 224-3900 |
News Archive
Two multi-gene tests designed to predict the risk of disease progression and response to chemotherapy in breast cancer produce broadly similar results for high- and low-risk patients, but do not always agree in their predictions for those at intermediate risk, a new analysis shows.
Physicians' Reciprocal Insurers, the second largest medical malpractice insurer in New York state, today announced that its physician communication course "Tuning In: Communication Skills for Partnering with Patients" has been honored as the winner of the 2010 Chief Learning Officer Gold Award in the "Excellence in E-Learning" category.
DANPACE, a Danish multicentre randomised trial comparing single lead atrial and dual chamber pacing in patients with sick sinus syndrome, concludes that dual chamber pacing, which was associated with lower rates of atrial fibrillation and re-operation, "should be the preferred pacing mode".
"Fifteen months before the midterm congressional election, health care is appearing in candidate stump speeches and interviews - particularly by Republican challengers… running in districts recently claimed by Democrats," USA Today reports.
Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.
› Verified 2 days ago
Alice S. Gibson, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1600 Pacific Ave, Natrona Heights, PA 15065 Phone: 724-224-3900 Fax: 724-224-9010 | |
Kristin Frederick, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1600 Pacific Ave, Natrona Heights, PA 15065 Phone: 724-224-3900 Fax: 724-224-9010 | |
Lorraine Chesek, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1600 Pacific Ave, Level 3 - Cow Pod, Natrona Heights, PA 15065 Phone: 724-224-3900 | |
Dr. Supriya Kar Atianand, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1600 Pacific Ave, Natrona Heights, PA 15065 Phone: 724-224-3900 Fax: 724-224-9010 | |
Dannika Totton, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1600 Pacific Ave, Natrona Heights, PA 15065 Phone: 724-224-3900 | |
Daniel Zove, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1600 Pacific Ave, Natrona Heights, PA 15065 Phone: 724-224-3900 |